# A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

> **NCT07071090** · PHASE1 · RECRUITING · sponsor: **Heronova Pharmaceuticals** · enrollment: 32 (estimated)

## Conditions studied

- Solid Tumor Malignancies

## Interventions

- **DRUG:** DC50292A

## Key facts

- **NCT ID:** NCT07071090
- **Lead sponsor:** Heronova Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07071090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07071090, "A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07071090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*